Nexalin Technology Inc. (NXL)
NXL trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/0001829126-26-002673-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NXL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001527352 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $302K |
| Net income | -$8.2M |
| Operating income | -$8.4M |
| Net margin | -2725.8% |
| Operating margin | -2781.7% |
| Revenue growth | +78.8% |
| Cash | $655K |
| Total assets | $4.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $793K cash; operating cash flow -$1.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,236,560 (2026-11-10); 18,651,939 a year earlier; 7,436,562 three years earlier. 1y figure adjusted for split (1-for-30 overall); 3y figure adjusted for split (1-for-30 overall). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2026-08-31 | Source 2026-08-31 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-20 |
| Exchange deficiency notices, 12 months | 4 (8-K item 3.01) | 8-K 2026-09-28 |
| Delisting | 25-NSE filed | 25-NSE 2025-09-19 |
| Auditor | CBIZ CPAs P.C., Marlton, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $78K | -$2.7M | -$1.6M | $793K | $953K | $277K | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $12K | -$2.2M | -$1.8M | $1.0M | No debt tags | $217K | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $15K | -$2.1M | -$1.7M | $1.2M | No debt tags | $276K | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $172K | -$2.4M | -$1.1M | $655K | No debt tags | $302K | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $18K | -$2.3M | -$1.5M | $590K | No debt tags | $157K | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $71K | -$1.6M | -$917K | $431K | No debt tags | $175K | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $41K | -$2.0M | -$1.4M | $622K | No debt tags | $131K | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $27K | -$2.8M | -$1.1M | $574K | No debt tags | $169K | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1/A | 2026-10-08 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-10-01 |
| Latest proxy | DEF 14A | 2026-11-06 |
Source: SEC EDGAR submissions feed, 207 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.7% |
| 1 month | -43.9% |
| 3 months | -85.9% |
| Year to date | -91.2% |
| 1 year | -95.8% |
| From 52-week high | -95.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NUWE | Nuwellis Inc. | $4.48 | -8.57% | $2.4M |
| VBIO | Valion Bio Inc. | $0.5290 | +0.84% | $1.1M |
| NDRA | ENDRA Life Sciences Inc. | $4.42 | -1.78% | $6.6M |
| IRIX | IRIDEX Corporation | $0.6878 | -0.32% | $12.1M |
| ITOC | iTonic Holdings Ltd | $1.88 | -5.05% | $13.8M |
| QTI | QT Imaging Holdings Inc. | $1.80 | -4.26% | $26.4M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier